ESTEVE is an international specialty pharmaceutical company that focuses on developing and manufacturing highly specialized treatments for areas with significant unmet medical needs. Headquartered in Barcelona, Spain, the company has a global presence with affiliates and manufacturing sites in Europe, Asia, and the Americas.

Company Overview

Founded:
1929

Headquarters:
Barcelona, Spain

Mission:
Improving people’s lives

Key Therapeutic Areas:
Neurology, pain management, rare diseases, and oncology

Business Model:
The company operates through two main divisions:

Pharma Business:
Focuses on the research, development, and commercialization of innovative specialty medicines.

CDMO Business (Contract Development and Manufacturing Organization):
Esteve Química provides contract manufacturing services for Active Pharmaceutical Ingredients (APIs) and intermediates to other pharmaceutical and biotech companies.
Key Activities & Strategy

ESTEVE’s strategy involves significant investment in research and development (R&D) and strategic acquisitions to expand its portfolio in specialized medicines. Notable recent activities include:

Acquisitions:
Acquiring companies and product rights to strengthen its presence in rare diseases and other specialized areas, such as the acquisition of HRA Pharma Rare Diseases in 2024 and an agreement to acquire Caprelsa® for medullary thyroid cancer in 2025.

Manufacturing Expansion:
The company is investing heavily in expanding its manufacturing capabilities, including a new €100 million API manufacturing unit in Spain and the acquisition of Regis Technologies to establish a physical CDMO presence in the United States.

Sustainability:
ESTEVE is committed to sustainability, using 100% renewable energy in its Spanish plants and aiming for net-zero emissions by 2050.
ESTEVE’s products and services reach more than 8 million patients worldwide, with international sales accounting for a significant portion of its revenue.